Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

106.95 -1.66 (-1.53%)
Official Closing Price Updated: 7:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,249,864
Open 107.04
Bid (Size) 105.90 (1)
Ask (Size) 106.90 (1)
Prev. Close 108.61
Today's Range 104.14 - 107.61
52wk Range 96.53 - 148.15
Shares Outstanding N/A
Dividend Yield 0.96%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study shows a low absolute risk despite significant association. 
Via Benzinga

Performance

YTD
+4.74%
+4.74%
1 Month
+0.04%
+0.04%
3 Month
-21.93%
-21.93%
6 Month
-24.95%
-24.95%
1 Year
+9.13%
+9.13%

More News

Read More
3 Growth Stocks That Can Be No-Brainer Buys in 2025
Via The Motley Fool
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Via Benzinga
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Via Benzinga
Despite its growth, NYSE:NVO remains within the realm of affordability.
Via Chartmill
2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
4 Stocks That Crushed Analyst Estimates by More Than Double
Via MarketBeat
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Via The Motley Fool
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Via Investor's Business Daily
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Via MarketBeat
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
Via Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
Via Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
Via Talk Markets
Topics Stocks / Equities
Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.